Article Per Year (5 Year)
p-Index From 2021 - 2026
2.062
P-Index
This Author published in this journals
All Journal Jurnal Kesehatan Andalas Majalah Kedokteran Andalas Jurnal Ilmu Kesehatan Indonesia (JIKSI) The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy Jurnal Penyakit Dalam Indonesia Jurnal Otorinolaringologi Kepala dan Leher Indonesia (JOKLI) Jurnal Sains, Teknologi dan Kesehatan
Saptino Miro, Saptino
Unknown Affiliation
Computer Science & IT Engineering Health Professions Immunology & microbiology Materials Science & Nanotechnology Medicine & Pharmacology Public Health

Published : 13 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 13 Documents
Search

 1   2 
Hubungan Pemakaian Obat Antiinflamasi Nonsteroid (OAINS) dengan Derajat Keparahan Dispepsia pada Pasien Osteoartritis di Wilayah Kerja Puskesmas Kuranji Kota Padang Muhammad Fadli; Rustam, Erlina; Syahrul, Muhammad Zulfadli; Usman, Elly; Miro, Saptino; Kadri, Husnil
Majalah Kedokteran Andalas Vol. 48 No. 4 (2025): MKA October 2025
Publisher : Faculty of Medicine, Universitas Andalas

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.25077/mka.v48.i4.p373-382.2025

Abstract

Latar Belakang: Di layanan primer, OA sering ditangani dengan OAINS, namun efek samping gastrointestinal seperti dispepsia kerap menurunkan kualitas hidup. Objektif: Menilai hubungan pemakaian OAINS dan durasinya dengan derajat keparahan dispepsia pada pasien OA di wilayah kerja Puskesmas Kuranji, Kota Padang. Metode: Studi potong lintang menggunakan data primer melalui wawancara terstruktur terhadap 101 pasien OA yang sedang menjalani terapi OAINS. Analisis menggunakan uji chi square. Hasil: Mayoritas responden berusia >60 tahun 54,5 persen, perempuan 79,2 persen. Natrium Diklofenak merupakan OAINS tersering 84,2 persen, dengan durasi penggunaan >3 bulan 56,4 persen. Terdapat hubungan pemakaian OAINS dengan dispepsia p=0,000, dan hubungan durasi penggunaan OAINS dengan derajat keparahan dispepsia p=0,001. Kesimpulan: Pada pasien OA di layanan primer, pemakaian dan durasi OAINS berkaitan dengan dispepsia dan tingkat keparahannya. Temuan ini menegaskan pentingnya skrining gejala cerna, edukasi pasien, serta peninjauan regimen analgesik yang lebih aman. Pertimbangkan gastroproteksi dan pemantauan berkala pada kelompok berisiko tinggi secara klinis.
Kadar Transthyretin Plasma pada Lanjut Usia Sarkopenia dan Non-Sarkopenia Fahrurozi, R. Ifan A.; Martini, Rose D; Mulyana, Roza; Murni, Arina W; Decroli, Eva; Miro, Saptino; Viotra, Deka; Yoga, Vesri
Jurnal Penyakit Dalam Indonesia Vol. 12, No. 4
Publisher : UI Scholars Hub

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Introduction. Sarcopenia is a geriatric syndrome marked by an age-related decline in muscle mass, which is affected by protein intake. Transthyretin is a visceral protein used to evaluate nutritional status and acts as a positive regulator of muscle mass. This study aimed to assess the difference in plasma transthyretin levels between elderly groups with and without sarcopenia. Methods. This was an analytical observational study with a cross-sectional approach. Subjects were elderly patients who visited the Internal Medicine Polyclinic of Dr. M. Djamil Hospital Padang and met the inclusion and exclusion criteria from August to September 2024. Subjects were classified into sarcopenic and non-sarcopenic groups, followed by an examination of plasma transthyretin levels. Sarcopenia was diagnosed using bio-impedance analysis (BIA) measurement, handgrip strength with a Jamar hydraulic hand dynamometer, and physical performance with a walking speed test. Plasma transthyretin levels were measured using the enzyme-linked immunosorbent assay (ELISA) method. Comparative analysis was performed using the unpaired T-test using SPSS 29.0. Results. Among total of 46 subjects who participated in this study, the majority of elderly individuals with sarcopenia were predominantly female. The mean plasma transthyretin level in the sarcopenic elderly group was 10.9 (3.3) mg/dL, while in the non-sarcopenic elderly group was 20.3 (2.5) mg/dL. Comparative analysis demonstrated a significant difference in plasma transthyretin levels between sarcopenic and non-sarcopenic elderly individuals (p < 0.001). Plasma transthyretin levels in the sarcopenic elderly group were lower compared to the non-sarcopenic elderly group. Conclusion. There is a significant difference in plasma transthyretin levels between sarcopenic and non-sarcopenic elderly individuals.
The Role of Immunotherapy in Hepatocellular Carcinoma (HCC) Fatimah, Nurhayani; Yoga, Vesri; -, Arnelis; Miro, Saptino
The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy Vol 27, No 1 (2026): VOLUME 27, NUMBER 1, April, 2026
Publisher : The Indonesian Society for Digestive Endoscopy

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24871/271202670-79

Abstract

Hepatocellular carcinoma (HCC) is an aggressive primary liver malignancy with a historically poor prognosis and limited treatment options. It accounts for approximately 75–85% of all liver cancer cases worldwide, with an estimated global incidence of about 9.5 per 100,000 person-years. According to GLOBOCAN 2022, the liver cancer mortality-to-incidence ratio in Indonesia is 0.99, indicating that nearly all patients diagnosed with HCC die from the disease. Systemic therapy, primarily sorafenib, a targeted therapy approved since 2007, has long been the mainstay for advanced cases, but it offers limited clinical benefit. In recent years, immunotherapy, particularly immune checkpoint inhibitors (ICIs), has significantly altered the therapeutic approach to HCC. These agents function by inhibiting regulatory pathways such as PD-1/PD-L1 and CTLA-4, thereby enhancing immune-mediated tumor clearance. Clinical trials, such as IMbrave150, have shown that combining atezolizumab and bevacizumab leads to notable improvements in both overall and progression-free survival compared to sorafenib, resulting in its approval as a first-line treatment. Similarly, combinations like durvalumab with tremelimumab have shown encouraging efficacy. Nonetheless, therapeutic resistance remains a challenge, often driven by the immunosuppressive tumor microenvironment. Emerging strategies, such as next-generation checkpoint blockades, adoptive cell therapy, therapeutic cancer vaccines, and oncolytic virotherapy, are under investigation to improve response rates. This review discusses current progress in immunotherapy for HCC, addresses clinical limitations, and explores potential future directions to enhance treatment success.
Co-Authors -, Arnelis Ade Asyari Almurdi Almurdi Andry Kurniawan Arnelis . Arnelis Arnelis Arni Amir Cimi Ilmiawati, Cimi Decroli, Rezeki Penta Deddy Saputra Deka Viotra Dwitya Elvira, Dwitya Endrinaldi Erlina Rustam Eti Yerizel Eva Decroli F, Annisa Maida Fadrian, Fadrian Fahrurozi, R. Ifan A. Fahrurozi, R. Ifan Arief Fatimah, Nurhayani Husnil Kadri Irwan Kam, Alexander Lili Irawati Martini, Rose D Monica, Febrina Muchtar, Masrul Muhammad Fadli Murni, Arina W Nabila, Fathiya Sarah Nasrul Zubir Putri, Athifa Alya Putri, Viona Salsabila Rahimi, Abdul Alim Ranazeri, Jersivindo Rashieka, Shaydi Amala Rinal Effendi Rita Hamdani Rosfita Rasyid Roza Mulyana Setiawan, Mentari Adinda Steven, Rios Syahrul, Muhammad Zulfadli Syandrez Prima Putra Ulya Uti Fasrini Vesri Yoga Wahyudi . Yulia, Dwi Yustini Alioes